Neurology Advocacy Service

  Press release on behalf of Veriton Pharma Ltd Published online: 2/10/17 Veriton Pharma Ltd is announced as the new company name for Special Products Ltd. This name change has occurred both to incorporate the company’s past heritage with its future ambitions to make trusted medicines available for everyday living. The Chief Commercial Officer commented: With the […]

Press release on behalf of Merck

  Real-World Data Further Support Efficacy of Dimethyl Fumarate in Newly Diagnosed and Early Switch Patients MS Patients with High Disease Activity Benefit from Early and Continued Natalizumab Treatment. Biogen have announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may […]

Results from the first randomised, controlled trial investigating the efficacy and safety of APO-go®/MOVAPO® (apomorphine) subcutaneous infusion in Parkinson’s disease (PD) patients whose motor symptoms are not controlled by other therapies – the TOLEDO study – were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, USA, […]